Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Comparative Efficacy of Metformin vs. Pioglitazone alone and in Combination with High Dose Oral Cholecalciferol among Women with Polycystic Ovary Syndrome (PCOS): A Six-month Randomized, Open Label Study
View through CrossRef
Purpose: We aimed to evaluate the comparative efficacy of metformin and pioglitazone coadministered with high dose VD on clinical, biochemical, hormonal and insulin sensitivity parameters in women with PCOS. Material and Methods: In this open label randomised study, a total of 136 women, aged 18-40 years, diagnosed with PCOS as per the AE PCOS 2009 criteria, were randomly assigned into four groups (n=34 per group). The four groups received Metformin-1gm/day alone, metformin-1gm/day+cholecalciferol4000IU/ d,pioglitazone-30mg/day alone and pioglitazone- 30mg/day+cholecalciferol-4000IU/d.The clinical, biochemical, hormonal and insulin sensitivity parameters were evaluated at 0, 3 months and 6 months after the intervention. Results: The mean age of subjects was 21.89±4.99 years with mean BMI of 22.19±3.24kg/m2. The mean serum 25OHD level at the baseline in the metformin+VD and pioglitazone+VD group was 13.28±8.44ng/ml and 11.17±7.46ng/ml and it improved to 63.33±19.76ng/ml and 57.69±14.43ng/ ml respectively after six months of intervention. The mean no. of cycles/year and Ferriman-Gallwey (FG) score improved in all four arms. Significant decrease in the total serum testosterone level was observed in the groups that received VD in addition to metformin and pioglitazone, the effect being more significant in the metformin+VD group (64.60±23.59ng/dl at 0 months to 41.24±12.83ng/dl after 6 months). Plasma glucose and insulin levels from a two-hour OGTT showed a significant improvement in subjects receiving VD in addition to pioglitazone. Conclusion: Metformin and pioglitazone are equally efficacious for treatment of women with PCOS. High dose oral cholecalciferol co-administration significantly improved the metabolic outcomes among these women. Key words: Metformin; Pioglitazone; PCOS; Insulin resistance; Vitamin D deficiency.
Red Flower Publication Private, Ltd.
Title: Comparative Efficacy of Metformin vs. Pioglitazone alone and in Combination with High Dose Oral Cholecalciferol among Women with Polycystic Ovary Syndrome (PCOS): A Six-month Randomized, Open Label Study
Description:
Purpose: We aimed to evaluate the comparative efficacy of metformin and pioglitazone coadministered with high dose VD on clinical, biochemical, hormonal and insulin sensitivity parameters in women with PCOS.
Material and Methods: In this open label randomised study, a total of 136 women, aged 18-40 years, diagnosed with PCOS as per the AE PCOS 2009 criteria, were randomly assigned into four groups (n=34 per group).
The four groups received Metformin-1gm/day alone, metformin-1gm/day+cholecalciferol4000IU/ d,pioglitazone-30mg/day alone and pioglitazone- 30mg/day+cholecalciferol-4000IU/d.
The clinical, biochemical, hormonal and insulin sensitivity parameters were evaluated at 0, 3 months and 6 months after the intervention.
Results: The mean age of subjects was 21.
89±4.
99 years with mean BMI of 22.
19±3.
24kg/m2.
The mean serum 25OHD level at the baseline in the metformin+VD and pioglitazone+VD group was 13.
28±8.
44ng/ml and 11.
17±7.
46ng/ml and it improved to 63.
33±19.
76ng/ml and 57.
69±14.
43ng/ ml respectively after six months of intervention.
The mean no.
of cycles/year and Ferriman-Gallwey (FG) score improved in all four arms.
Significant decrease in the total serum testosterone level was observed in the groups that received VD in addition to metformin and pioglitazone, the effect being more significant in the metformin+VD group (64.
60±23.
59ng/dl at 0 months to 41.
24±12.
83ng/dl after 6 months).
Plasma glucose and insulin levels from a two-hour OGTT showed a significant improvement in subjects receiving VD in addition to pioglitazone.
Conclusion: Metformin and pioglitazone are equally efficacious for treatment of women with PCOS.
High dose oral cholecalciferol co-administration significantly improved the metabolic outcomes among these women.
Key words: Metformin; Pioglitazone; PCOS; Insulin resistance; Vitamin D deficiency.
Related Results
O-105 Chromatin accessibility of oocytes contributes to PCOS transgenerational inheritance
O-105 Chromatin accessibility of oocytes contributes to PCOS transgenerational inheritance
Abstract
Study question
What is the underlying mechanism contributing to the transgenerational defects of oocytes and embryos of...
INVESTIGATING CARDIOVASCULAR AND METABOLIC HEALTH PROFILES IN WOMEN WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME: INSIGHTS FROM DISTRICT GHOTKI
INVESTIGATING CARDIOVASCULAR AND METABOLIC HEALTH PROFILES IN WOMEN WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME: INSIGHTS FROM DISTRICT GHOTKI
Background: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that impacts women’s reproductive and metabolic health. PCOS is frequently associated with increased ...
The discriminative role of angiopoietin-like protein-3 for metabolic syndrome in polycystic ovary syndrome
The discriminative role of angiopoietin-like protein-3 for metabolic syndrome in polycystic ovary syndrome
SUMMARY OBJECTIVE: Patients with polycystic ovary syndrome face an increased risk of developing metabolic syndrome. Identifying biomarkers that can detect metabolic syndrome in po...
P-326 No higher incidence of chronic endometritis in infertile women with polycystic ovary syndrome: a propensity score-matched study
P-326 No higher incidence of chronic endometritis in infertile women with polycystic ovary syndrome: a propensity score-matched study
Abstract
Study question
Do infertile women with polycystic ovary syndrome(PCOS) have a higher incidence of chronic endometritis(...
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract
BACKGROUND
Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer agent...
Investigation of Inflammatory Markers in Patients with Polycystic Ovary Syndrome Receiving and Not Receiving Metformin Treatment
Investigation of Inflammatory Markers in Patients with Polycystic Ovary Syndrome Receiving and Not Receiving Metformin Treatment
Background and Objectives: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. The etiology of PCOS is complex and is assoc...
AN UPDATED OVERVIEW OF POLYCYSTIC OVARY SYNDROME
AN UPDATED OVERVIEW OF POLYCYSTIC OVARY SYNDROME
Polycystic ovary syndrome (PCOS), also known as Stein-Leventhal Syndrome, was first described in 1935. PCOS, which may also be referred to as polycystic ovary disease is the most c...
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract
Background: Metformin, an oral biguanide used for the treatment of type-2 diabetes mellitus (DM), has been shown in a considerable number of studies to have...